Abstract:Genetic alterations (homozygous [biallelic] deletion and mutation) of BRCA1 BAP1 have been frequently observed and described as a critical event in the pathogenesis of malignant pleural mesothelioma (MPM) (Fig. 1A).1Testa J.R. Cheung M. Pei J. et al.Germline BAP1 mutations predispose to malignant mesothelioma.Nat Genet. 2011; 43: 1022-1025Crossref PubMed Scopus (761) Google Scholar As BAP1 is a tumor suppressor, its canonical roles are involved in the maintenance of genomic stability and the repair of DNA double-strand breaks (DSBs).2Yu H. Pak H. Hammond-Martel I. et al.Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.Proc Natl Acad Sci U S A. 2014; 111: 285-290Crossref PubMed Scopus (241) Google Scholar Thus, BAP1 loss-of-function is associated with defects in the repair of DSBs.2Yu H. Pak H. Hammond-Martel I. et al.Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.Proc Natl Acad Sci U S A. 2014; 111: 285-290Crossref PubMed Scopus (241) Google Scholar Given that poly(adenosine diphosphate–ribose) polymerase (PARP)–targeted therapies exhibit a synthetically lethal effect in tumors defective in homologous recombination repair of DSBs, susceptibility to PARP-targeted therapies has been revealed in cancer cells harboring BAP1 loss-of-function, including MPM.2Yu H. Pak H. Hammond-Martel I. et al.Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.Proc Natl Acad Sci U S A. 2014; 111: 285-290Crossref PubMed Scopus (241) Google Scholar,3Parrotta R. Okonska A. Ronner M. et al.A novel BRCA1-associated Protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.J Thorac Oncol. 2017; 12: 1309-1319Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar In a recent study, Rathkey et al.4Rathkey D. Khanal M. Murai J. et al.Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-Schlafen 11 and low-O6-methylguanine-DNA methyltransferase expression [e-pub ahead of print]. J Thorac Oncol.https://doi.org/10.1016/j.jtho.2020.01.012Google Scholar investigated the association of genetic alterations of BAP1 with the sensitivity to PARP inhibition in a panel of patient-derived primary MPM cells harboring various types of BAP1 alterations. Surprisingly, in contrast with previous studies,2Yu H. Pak H. Hammond-Martel I. et al.Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.Proc Natl Acad Sci U S A. 2014; 111: 285-290Crossref PubMed Scopus (241) Google Scholar,3Parrotta R. Okonska A. Ronner M. et al.A novel BRCA1-associated Protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.J Thorac Oncol. 2017; 12: 1309-1319Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar this work revealed that the sensitivity of MPM cells to PARP inhibitors is independent of BAP1 mutational status. To carry out cross-validation, we integrated the high-throughput drug screen data from the publicly available database, Genomics of Drug Sensitivity in Cancer (https://www.cancerrxgene.org/), which assays hundreds of drug compounds containing several selective PARP inhibitors on approximately 1000 human cancer cell lines including MPM (n = 20) and the genetic landscape of the respective cell lines on the basis of the Cancer Cell Line Encyclopedia project. We extracted the drug sensitivity data of MPM cell lines and observed a fraction of these cell lines, including BAP1-altered (H2804, IST-MES1, and H2795) and wild-type (H2803 and MSTO-211H) that are particularly sensitive to PARP inhibitors. This is determined by the low IC50 z-score (≤ -1) to various PARP1 inhibitors (talazoparib, olaparib, veliparib, and rucaparib) compared with that of other molecule-targeted agents (Fig. 1B). Notably, some BAP1-mutant MPM cells (H2452, H2731, and H2722) are even more highly resistant to multiple PARP inhibitors. These data suggest that BAP1-mutant MPM cells display highly heterogeneous susceptibility to PARP inhibitors, which provides an additional layer of evidence supporting the work of Rathkey et al.4Rathkey D. Khanal M. Murai J. et al.Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-Schlafen 11 and low-O6-methylguanine-DNA methyltransferase expression [e-pub ahead of print]. J Thorac Oncol.https://doi.org/10.1016/j.jtho.2020.01.012Google Scholar This high heterogeneity might be explained by the following: (1) the presence of co-occurring mutations with genetic alterations of BAP1 in MPM (Fig. 2), which might lead to the varying responses to PARP inhibitors given that tumorigenesis is a complex process involving a gradual accumulation of genetic alterations; (2) some specific BAP1 splice isoform can affect the response to PARP inhibition,3Parrotta R. Okonska A. Ronner M. et al.A novel BRCA1-associated Protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.J Thorac Oncol. 2017; 12: 1309-1319Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar indicating that further stratifications might be warranted to guide PARP-targeted therapy among patients with BAP1-mutant MPM; (3) BAP1 has multifaceted functions beyond its involvement in the genomic stability and repair of DSBs,5Zhang Y. Shi J. Liu X. et al.BAP1 links metabolic regulation of ferroptosis to tumour suppression.Nat Cell Biol. 2018; 20: 1181-1192Crossref PubMed Scopus (366) Google Scholar implying that subtype-specific alterations might result in different biological aberrations; and (4) the cell lineage (MPM versus non-MPM) might play a role in the response to PARP inhibition. In summary, BAP1 mutational status in MPM does not seem to affect the sensitivity to PARP-targeted therapy. Further studies investigating the association of BAP1-mutational status with homologous recombination deficiency and sensitivity to PARP inhibition are required. This work was supported by PhD fellowship from the China Scholarship Council (to Dr. Yang and Dr. Gao) and a grant from Swiss Cancer League/Swiss Cancer Research (#KFS-4851-08-2019; to Dr. Peng). Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase ExpressionJournal of Thoracic OncologyVol. 15Issue 5PreviewBRCA1-associated protein-1 (BAP1), a nuclear deubiquitinase thought to be involved in DNA double-strand break repair, is frequently mutated in mesothelioma. Because poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPIs) induce synthetic lethality in BRCA1/2 mutant cancers, we evaluated whether BAP1 inactivating mutations confer sensitivity to PARPIs in mesothelioma and if combination therapy with temozolomide (TMZ) would be beneficial. Full-Text PDF Open Archive

Abstract 1468: Low exposures to amphibole or serpentine asbestos in germline Bap1 -mutant mice induce mesotheliomacharacterized by an immunosuppressive tumor microenvironment

BAP1 Forms a Trimer with HMGB1 and HDAC1 That Modulates Gene × Environment Interaction with Asbestos.

Abstract 7545: Epigenetic plasticity in rewiring DNMT1/UHRF1-RB1- NFkB signaling circuit regulates asbestos-induced mesothelial malignant transformation

Abstract 5519: BAP1 Modulates Gene-Environment Interaction in Carcinogenesis

Inflammation-Related IL1β/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma

Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma

A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma.

Medical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations

Abstract 1473: Exposure of arsenic promotes malignant stemness and induces bladder malignancy in preclinical models

BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma

Asbestos Induces Activator Protein-1 Transactivation In Transgenic Mice

The Association of BAP1 Loss-of-Function with the Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy

Abstract 5367: Single cell resolution spatial transcriptomics reveals genetic driver and TME interaction in clear cell renal cell carcinoma

Abstract A061: A novel genetically engineered mouse model of Myc-driven pancreatic cancer recapitulates phenotypic heterogeneity, metastasis, and therapy resistance seen in clinical populations

Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer

Abstract 7334: Germline mutations in cancer susceptibility genes in patients with mucosal melanoma

Abstract 3471: Reciprocal Roles of Cytochromes P4501A1 and 1A2 in Polycyclic Aromatic Hydrocarbon (Pah)-Mediated Tumorigenesis in Mice: Implications for Lung Cancer in Humans

Crocidolite asbestos-induced signal pathway dysregulation in mesothelial cells.

Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy

Abstract 919: APOBEC3 promotes tumor progression, squamous differentiation and metastasis in bladder cancer mouse model

Abstract 3017: Lack of MCPIP1 enzymatic activity leads to neoplastic transformation of normal kidney cells